Yan Xie Selected Research

Extranodal NK-T-Cell Lymphoma

9/2022	Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
9/2018	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
12/2016	Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome.
7/2013	A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type.
7/2009	L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yan Xie Research Topics

Disease

71	Neoplasms (Cancer) 02/2022 - 09/2007
24	Infections 01/2022 - 08/2011
15	Breast Neoplasms (Breast Cancer) 02/2022 - 07/2009
12	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2009
12	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 04/2003
11	Chronic Renal Insufficiency 12/2020 - 01/2014
10	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 12/2012
10	Obesity 01/2021 - 11/2006
9	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 10/2011
9	COVID-19 01/2022 - 06/2020
9	Fibrosis (Cirrhosis) 02/2021 - 07/2002
9	Chronic Kidney Failure (Chronic Renal Failure) 11/2020 - 04/2016
8	Inflammation (Inflammations) 01/2022 - 02/2011
8	Stomach Neoplasms (Stomach Cancer) 12/2021 - 01/2016
8	Hypoxia (Hypoxemia) 01/2020 - 12/2004
7	Tuberculosis (Tuberculoses) 01/2022 - 11/2015
7	Prostatic Neoplasms (Prostate Cancer) 02/2021 - 07/2007
7	Lymphoma (Lymphomas) 01/2021 - 10/2011
7	Kidney Diseases (Kidney Disease) 01/2020 - 01/2014
6	Necrosis 09/2022 - 07/2008
6	Cicatrix (Scar) 08/2022 - 11/2010
6	Asthma (Bronchial Asthma) 01/2022 - 09/2010
6	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 03/2006
6	Type 2 Diabetes Mellitus (MODY) 01/2022 - 06/2007
6	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 10/2011
6	Weight Gain 01/2021 - 11/2004
6	Carcinogenesis 01/2021 - 01/2010
6	Hypersensitivity (Allergy) 01/2021 - 09/2000
5	Extranodal NK-T-Cell Lymphoma 09/2022 - 07/2009
5	Hypertrophic Cicatrix (Hypertrophic Scar) 08/2022 - 11/2010
5	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2014
5	Body Weight (Weight, Body) 01/2021 - 07/2002
5	Respiratory Hypersensitivity 11/2020 - 08/2012
5	Colorectal Neoplasms (Colorectal Cancer) 10/2020 - 09/2007
5	Wounds and Injuries (Trauma) 06/2019 - 06/2008
5	Gallstones (Gallstone) 01/2017 - 05/2009
4	Burns 11/2022 - 08/2011
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 04/2015
4	Hemorrhage 05/2022 - 01/2014
4	Liver Neoplasms (Liver Cancer) 01/2022 - 01/2014
4	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2013
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2021 - 01/2010
4	Liver Diseases (Liver Disease) 09/2018 - 07/2009
4	Ischemia 01/2018 - 06/2005
4	Fatty Liver 01/2017 - 07/2005
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2016 - 05/2012

Drug/Important Bio-Agent (IBA)

42	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2007
13	Pharmaceutical PreparationsIBA 02/2022 - 08/2015
13	Messenger RNA (mRNA)IBA 01/2020 - 09/2007
12	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2016
12	LipidsIBA 01/2022 - 11/2004
10	Long Noncoding RNAIBA 01/2022 - 11/2019
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 11/2008
10	CholesterolIBA 01/2021 - 02/2006
9	Biological ProductsIBA 01/2022 - 07/2007
9	CreatinineIBA 11/2021 - 01/2014
8	O(4)-methylthymidine triphosphateIBA 01/2021 - 02/2006
8	CytokinesIBA 11/2019 - 02/2011
7	Asparaginase (Elspar)FDA Link 09/2022 - 03/2006
7	CollagenIBA 08/2022 - 02/2015
7	MicroRNAs (MicroRNA)IBA 12/2021 - 01/2014
7	Particulate MatterIBA 01/2021 - 10/2017
7	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2007
7	Rituximab (Mabthera)FDA Link 01/2019 - 01/2007
6	Therapeutic UsesIBA 09/2022 - 01/2007
6	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 07/2015 - 07/2009
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 10/2009
5	Viral DNAIBA 01/2022 - 08/2011
5	Bile Acids and Salts (Bile Acids)IBA 01/2022 - 06/2009
5	ChylomicronsIBA 01/2021 - 01/2012
5	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 07/2013
5	FructoseIBA 01/2021 - 01/2017
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 07/2013
5	Oxygen (Dioxygen)IBA 01/2021 - 02/2010
5	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2008
5	Proton Pump InhibitorsIBA 01/2020 - 08/2011
5	microsomal triglyceride transfer proteinIBA 10/2019 - 01/2012
5	AcidsIBA 01/2019 - 01/2008
5	Small Interfering RNA (siRNA)IBA 01/2019 - 07/2009
5	EnzymesIBA 12/2017 - 10/2011
4	QuercetinIBA 02/2022 - 09/2019
4	Hyaluronic Acid (Hyaluronan)IBA 02/2022 - 01/2017
4	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 01/2017
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 11/2020
4	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 10/2016
4	Competitive Endogenous RNAIBA 01/2022 - 11/2019
4	Chimeric Antigen ReceptorsIBA 02/2021 - 01/2019
4	CateninsIBA 01/2021 - 10/2013
4	shikoninIBA 01/2018 - 02/2015
4	Fatty Acid-Binding ProteinsIBA 01/2017 - 11/2006
4	AndrogensIBA 01/2017 - 07/2007
4	GTP-Binding Proteins (G-Protein)IBA 07/2015 - 07/2009
4	VenomsIBA 01/2015 - 11/2011
4	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2013 - 09/2010

Therapy/Procedure

48	Therapeutics 10/2022 - 06/2008
18	Drug Therapy (Chemotherapy) 02/2022 - 03/2006
6	Transplantation 12/2017 - 02/2013
5	Radiotherapy 01/2022 - 07/2013
4	Critical Care (Surgical Intensive Care) 01/2022 - 01/2021
4	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2021 - 03/2015